JP2009531283A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009531283A5 JP2009531283A5 JP2008552923A JP2008552923A JP2009531283A5 JP 2009531283 A5 JP2009531283 A5 JP 2009531283A5 JP 2008552923 A JP2008552923 A JP 2008552923A JP 2008552923 A JP2008552923 A JP 2008552923A JP 2009531283 A5 JP2009531283 A5 JP 2009531283A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- inhibitor
- cxcr4
- nucleotide sequence
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 15
- 230000002401 inhibitory effect Effects 0.000 claims 15
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 10
- 102100002212 CXCR4 Human genes 0.000 claims 7
- 101710003734 CXCR4 Proteins 0.000 claims 7
- 230000000295 complement Effects 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 102100014691 CXCL12 Human genes 0.000 claims 4
- 101710043128 CXCL12 Proteins 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 229940121384 CXC chemokine receptor type 4 (CXCR4) antagonists Drugs 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108020004999 Messenger RNA Proteins 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims 2
- 229920002106 messenger RNA Polymers 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 230000002207 retinal Effects 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 206010057430 Retinal injury Diseases 0.000 claims 1
- 229920001914 Ribonucleotide Polymers 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 108091008117 polyclonal antibodies Proteins 0.000 claims 1
- 201000011056 retinal disease Diseases 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
Claims (16)
- 処置を必要とする哺乳動物の網膜組織に、CXCR4活性の阻害剤を含む組成物を投与することを含む、哺乳動物における網膜の障害を処置する方法。
- CXCR4活性の阻害剤が、
i)CXCR4 mRNA 翻訳活性の阻害剤、および
ii)SDF-1 mRNA翻訳活性の阻害剤、
からなる群から選択される、請求項1記載の方法。 - CXCR4活性の阻害剤が、
i)配列番号1のアミノ酸配列をコードするヌクレオチド配列の連続領域と厳密に相補的な少なくとも約12個の連続するヌクレオチドを有する第一の核酸領域、または
ii)第一の核酸領域と厳密に相補的な少なくとも12個の連続するヌクレオチドの第二の核酸領域、
を含む、請求項2記載の方法。 - 少なくとも一つの核酸領域が、リボヌクレオチド配列を含む、請求項1〜3のいずれかに記載の方法。
- 阻害剤が、下記ヌクレオチド配列:配列番号 10、配列番号 11、配列番号 12、配列番号 13、配列番号 14、配列番号 15、配列番号 16、配列番号 17、配列番号 18、配列番号 19、配列番号 20、配列番号 21、配列番号 22、配列番号 23、配列番号 24、配列番号 25、配列番号 26、配列番号 27、配列番号 28、配列番号 29、配列番号 30、配列番号 31、配列番号 32、配列番号 33、配列番号 34、配列番号 35、配列番号 36、配列番号 37、配列番号 38、配列番号 39、配列番号 40、配列番号 41、配列番号 42、配列番号 43、配列番号 44、配列番号 45、配列番号 46、配列番号 47、配列番号 48、配列番号 49、配列番号 50、配列番号 51、配列番号 52、配列番号 53、配列番号 54および配列番号 55の少なくとも一つを含む、請求項4記載の方法。
- 哺乳動物における網膜障害の進行速度を低下させる方法であって、
かかる低下を必要とする哺乳動物の網膜組織に、SDF-1またはCXCR4-選択的標的部位に選択的に結合するポリペプチド成分を含む阻害剤である、組成物を投与すること、ここで該ポリペプチド成分の結合がSDF-1またはCXCR4の細胞活性を阻害する、方法。
を含む方法。 - 阻害剤がCXCR4を選択的に結合する、請求項6記載の方法。
- 阻害剤が、天然または合成ポリクローナルまたはモノクローナル抗体の結合領域を含んでいるCXCR4アンタゴニストを含む、請求項7記載の方法。
- 阻害剤が、抗CXCR4 Fabフラグメント、抗CXCR4 Fab’フラグメントおよびこれらのうちの一つの組換え誘導体からなる群から選択される抗体フラグメントを含む、請求項8記載の方法。
- CXCR4 アンタゴニストが、抗CXCR4 抗体可変領域を含んでいる、請求項8記載の方法。
- 阻害剤がSDF-1を選択的に結合する、請求項6記載の方法。
- ポリペプチド成分がペプチド擬体である、請求項6記載の方法。
- 阻害剤が、配列番号 2、配列番号 3、配列番号 4、配列番号 5、配列番号 6、配列番号 7、配列番号 8および配列番号 9の少なくとも12個の連続するヌクレオチドのヌクレオチド配列領域に相補的なヌクレオチド配列を含む、請求項2記載の方法。
- 阻害剤が、配列番号 2、配列番号 3、配列番号 4、配列番号 5、配列番号 6、配列番号 7、配列番号 8および配列番号 9の少なくとも18個の連続するヌクレオチドのヌクレオチド配列領域に相補的なヌクレオチド配列を含む、請求項2記載の方法。
- 阻害剤が、配列番号 2、配列番号 3、配列番号 4、配列番号 5、配列番号 6、配列番号 7、配列番号 8および配列番号 9の少なくとも22個の連続するヌクレオチドのヌクレオチド配列領域に相補的なヌクレオチド配列を含む、請求項2記載の方法。
- 阻害剤が、配列番号 2、配列番号 3、配列番号 7、配列番号 8および配列番号 9の少なくとも25個の連続するヌクレオチドのヌクレオチド配列領域に相補的なヌクレオチド配列を含む、請求項2記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76489206P | 2006-02-02 | 2006-02-02 | |
PCT/IB2007/003262 WO2008029276A2 (en) | 2006-02-02 | 2007-02-02 | Compositions and methods for the treatment of ophthalmic disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009531283A JP2009531283A (ja) | 2009-09-03 |
JP2009531283A5 true JP2009531283A5 (ja) | 2010-03-25 |
Family
ID=39157630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008552923A Pending JP2009531283A (ja) | 2006-02-02 | 2007-02-02 | 眼系疾患の処置のための組成物および方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US7964191B2 (ja) |
EP (3) | EP2407171A3 (ja) |
JP (1) | JP2009531283A (ja) |
AU (1) | AU2007293169A1 (ja) |
BR (1) | BRPI0707446A2 (ja) |
CA (1) | CA2640080A1 (ja) |
ES (1) | ES2385924T3 (ja) |
WO (1) | WO2008029276A2 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004296376B2 (en) | 2003-12-05 | 2010-03-04 | Bristol-Myers Squibb Company | Inhibitors of type 2 vascular endothelial growth factor receptors |
US20080220049A1 (en) * | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
EP1852432A4 (en) * | 2005-02-25 | 2010-04-14 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUND AND THEIR MEDICAL USE |
US20090105182A1 (en) * | 2006-06-02 | 2009-04-23 | Alcon Research, Ltd. | RNAi-MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR 1-RELATED TARGETS FOR TREATMENT OF NEOVASCULARIZATION-RELATED CONDITIONS |
PL2041282T3 (pl) | 2006-07-18 | 2018-07-31 | Noxxon Pharma Ag | Kwasy nukleinowe wiążące sdf-i |
BRPI0719597A2 (pt) | 2006-11-22 | 2013-12-17 | Adnexus A Bristol Myers Squibb R & D Company | Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir |
US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
US8772257B2 (en) | 2007-08-06 | 2014-07-08 | Noxxon Pharma Ag | SDF-1 binding nucleic acids and the use thereof |
WO2009102421A2 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
JP2011520961A (ja) | 2008-05-22 | 2011-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | 多価フィブロネクチンをベースとする足場ドメインタンパク質 |
US11029313B2 (en) | 2008-09-26 | 2021-06-08 | The General Hospital Corporation | Method of treating cervical neoplasia in patients infected with human papilloma virus |
US9229004B2 (en) * | 2008-09-26 | 2016-01-05 | The General Hospital Corporation | Methods for detecting and treating cancer |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
US20100204325A1 (en) * | 2009-02-11 | 2010-08-12 | Allergan, Inc. | Valproic acid drug delivery systems and intraocular therapeutic uses thereof |
JP2013516495A (ja) | 2010-01-11 | 2013-05-13 | イノテック ファーマシューティカルズ コーポレイション | 眼圧を低下させる組合せ、キット、および方法 |
JP2013523739A (ja) | 2010-03-26 | 2013-06-17 | イノテック ファーマシューティカルズ コーポレイション | N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
WO2013006837A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Cationic oil-in-water emulsions |
EP3424495A1 (en) | 2011-07-06 | 2019-01-09 | GlaxoSmithKline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
BR112014018413A8 (pt) | 2012-01-26 | 2017-07-11 | Inotek Pharmaceuticals Corp | Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo |
CN105188714A (zh) | 2013-03-15 | 2015-12-23 | 伊诺泰克制药公司 | 眼用配制品 |
CN106211774B (zh) | 2013-08-02 | 2020-11-06 | 辉瑞公司 | 抗cxcr4抗体及抗体-药物缀合物 |
EP3038617A1 (en) | 2013-08-30 | 2016-07-06 | Ramot at Tel-Aviv University Ltd. | Method for treating amyotrophic lateral sclerosis by inhibition of cxcr4/cxcl12 signaling |
CN107708707B (zh) * | 2015-05-29 | 2021-09-07 | 生化学工业株式会社 | 包含糖胺聚糖衍生物和趋化因子受体活性调节材料的组合物 |
CA3004738A1 (en) * | 2015-11-09 | 2017-05-18 | Aperisys, Inc. | Modified immune cells and uses thereof |
CN109053697A (zh) * | 2018-09-27 | 2018-12-21 | 张淑华 | 一种用于抗癌的嘧啶类化合物及其制备方法 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
BR9106702A (pt) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals Inc | Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo |
KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
ATE204879T1 (de) | 1991-12-24 | 2001-09-15 | Isis Pharmaceuticals Inc | Antisense oligonukleotide |
US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
CA2140428C (en) | 1992-07-23 | 2003-07-08 | Daniel Peter Claude Mcgee | Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof |
WO1994019023A1 (en) | 1993-02-19 | 1994-09-01 | Isis Pharmaceuticals, Inc. | Cyclobutyl antisense oligonucleotides, methods of making and use thereof |
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
US5994515A (en) | 1996-06-25 | 1999-11-30 | Trustees Of The University Of Pennsylvania | Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same |
WO1999007418A2 (en) | 1997-08-11 | 1999-02-18 | Allergan Sales, Inc. | Sterile bioerodible implant device with improved biocompatability and method |
JP4312957B2 (ja) * | 1998-01-15 | 2009-08-12 | キングス・カレツジ・ロンドン | Ccr5あるいはcxcr4を開裂するリボザイム核酸 |
CA2245224A1 (en) | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
CA2305787A1 (en) | 2000-05-09 | 2001-11-09 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
JP2002506830A (ja) * | 1998-03-13 | 2002-03-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 治療的ケモカイン受容体アンタゴニスト |
ES2268854T3 (es) * | 1998-03-24 | 2007-03-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidores de la vascularizacion. |
WO1999062535A2 (en) | 1998-06-01 | 1999-12-09 | University Of Maryland Biotechnology Institute | Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases |
AU5241099A (en) | 1998-07-31 | 2000-02-21 | Trustees Of Columbia University In The City Of New York, The | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis |
US20050202005A1 (en) | 1998-07-31 | 2005-09-15 | The Trustees Of Columbia University In The City Of New York | Uses of inhibitors for the activation of CXCR4 receptor by SDF-1 in treating rheumatoid arthritis |
US20030099645A1 (en) | 2000-10-10 | 2003-05-29 | Lobo Peter Isaac | Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes |
US6610834B1 (en) | 1998-11-18 | 2003-08-26 | Peter I. Lobo | Human IgM antibodies to chemokine receptors |
US20050220787A1 (en) | 2002-11-07 | 2005-10-06 | Lobo Peter I | Naturally occuring IgM antibodies that bind to lymphocytes |
AU1408300A (en) | 1998-11-24 | 2000-06-13 | Hisamitsu Pharmaceutical Co. Inc. | Hiv infection inhibitors |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6949243B1 (en) | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
EP1244648B1 (en) * | 1999-12-17 | 2009-04-15 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds |
US20030220482A1 (en) | 2000-02-03 | 2003-11-27 | Ziwei Huang | Novel peptide antagonist of CXCR4 derived from the N-terminus of the viral chemokine vMIP-II |
AU2754600A (en) | 2000-02-04 | 2001-08-14 | Us Health | Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
JP2004508421A (ja) | 2000-09-15 | 2004-03-18 | アノーメッド インコーポレイティド | ケモカインレセプター結合性ヘテロ環式化合物 |
US20030165988A1 (en) | 2002-02-08 | 2003-09-04 | Shaobing Hua | High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins |
AU3649502A (en) | 2000-11-29 | 2002-06-11 | Oculex Pharm Inc | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
US20060019917A1 (en) | 2001-05-18 | 2006-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
US20050124569A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
WO2003102131A2 (en) * | 2002-04-22 | 2003-12-11 | Sirna Therapeutics Inc. | Nucleic acid mediated disruption of hiv fusogenic peptide interactions |
EP1389460A1 (en) | 2001-05-24 | 2004-02-18 | Kureha Chemical Industry Co., Ltd. | Cxcr4-antagonistic drugs comprising nitrogen-containing compound |
JPWO2003029218A1 (ja) | 2001-09-28 | 2005-01-13 | 呉羽化学工業株式会社 | 新規含窒素化合物及びその用途 |
US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
JP4556020B2 (ja) | 2001-12-21 | 2010-10-06 | ジェンザイム・コーポレーション | 高い有効性を有するケモカインレセプタ結合複素環式化合物 |
WO2003060521A2 (en) | 2001-12-31 | 2003-07-24 | Consejo Superior De Investigaciones Cientificas | Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
AU2003233576A1 (en) * | 2002-05-17 | 2003-12-02 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
EP1608318A4 (en) * | 2003-03-27 | 2009-07-29 | Univ Emory | CXCR4 ANTAGONISTS AND METHODS OF USE |
EP1613613B1 (en) | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
WO2005002522A2 (en) | 2003-06-30 | 2005-01-13 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for treating tissue ischemia |
US20050266009A1 (en) | 2003-06-30 | 2005-12-01 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
US20050019927A1 (en) * | 2003-07-13 | 2005-01-27 | Markus Hildinger | DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER |
JP2007523159A (ja) | 2004-02-20 | 2007-08-16 | ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド | Rna干渉分子の標的送達 |
EP1750691B1 (en) | 2004-03-26 | 2016-08-10 | Novaremed Ltd. | Compounds for treatment of aids and other diseases |
JP2008514709A (ja) * | 2004-10-01 | 2008-05-08 | メルク エンド カムパニー インコーポレーテッド | 眼科疾患を治療するための組成物および方法 |
AU2005309854A1 (en) * | 2004-11-24 | 2006-06-01 | Therakine Ltd. | An implant for intraocular drug delivery |
JP2008535779A (ja) * | 2005-01-07 | 2008-09-04 | エモリー・ユニバーシテイ | Hiv感染治療のためのcxcr4拮抗薬 |
WO2006074428A2 (en) * | 2005-01-07 | 2006-07-13 | Emory University | Cxcr4 antagonists for the treatment of medical disorders |
EP1852432A4 (en) | 2005-02-25 | 2010-04-14 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUND AND THEIR MEDICAL USE |
US20060257359A1 (en) * | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
DK1866414T3 (da) * | 2005-03-31 | 2012-04-23 | Calando Pharmaceuticals Inc | Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf. |
-
2007
- 2007-02-02 EP EP11177758A patent/EP2407171A3/en not_active Ceased
- 2007-02-02 WO PCT/IB2007/003262 patent/WO2008029276A2/en active Application Filing
- 2007-02-02 CA CA002640080A patent/CA2640080A1/en not_active Abandoned
- 2007-02-02 EP EP11177757A patent/EP2397148A3/en not_active Withdrawn
- 2007-02-02 JP JP2008552923A patent/JP2009531283A/ja active Pending
- 2007-02-02 US US11/670,883 patent/US7964191B2/en active Active
- 2007-02-02 ES ES07848839T patent/ES2385924T3/es active Active
- 2007-02-02 EP EP07848839A patent/EP1993584B1/en active Active
- 2007-02-02 BR BRPI0707446-8A patent/BRPI0707446A2/pt not_active Application Discontinuation
- 2007-02-02 AU AU2007293169A patent/AU2007293169A1/en not_active Abandoned
-
2011
- 2011-06-10 US US13/158,084 patent/US20120003275A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009531283A5 (ja) | ||
Schonthaler et al. | S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3 | |
JP2012012402A5 (ja) | ||
JP2017113019A5 (ja) | ||
JP2018502051A5 (ja) | ||
JP2019506159A5 (ja) | ||
JP2010516708A5 (ja) | ||
RU2008119689A (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
RS20070027A (en) | Anti-cd154 antibodies | |
JP2010510223A5 (ja) | ||
JP2006511584A5 (ja) | ||
IL168646A (en) | Antibodies binding to human magic roundabout (mr) and uses thereof for inhibition of angiogenesis | |
JP2010534469A5 (ja) | ||
AU2014268316B2 (en) | Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma | |
US9067989B2 (en) | Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders | |
JP2013539369A5 (ja) | ||
US9453050B2 (en) | Compositions for treating glioma | |
JP2018198596A5 (ja) | ||
JP2015508063A5 (ja) | ||
JP2010504336A5 (ja) | ||
JP2018501201A5 (ja) | ||
JP2005502319A5 (ja) | ||
JP2017535551A5 (ja) | ||
JP2005536220A5 (ja) | ||
JP2009526861A5 (ja) |